Fax: (404) 639-2980
Article first published online: 15 NOV 2002
Copyright © 2002 American Cancer Society
Volume 95, Issue 11, pages 2308–2315, 1 December 2002
How to Cite
Hall, H. I., Satariano, W. A., Thompson, T., Ragland, K. E., Van Den Eeden, S. K. and Selvin, S. (2002), Initial treatment for prostate carcinoma in relation to comorbidity and symptoms. Cancer, 95: 2308–2315. doi: 10.1002/cncr.10926
This article is a US Government work and, as such, is in the public domain in the United States of America.
Data collection supported by a cooperative agreement (U48/CCU909706) between the Centers for Disease Control and Prevention and the Center for Family and Community Health at the University of California, Berkeley.
- Issue published online: 19 NOV 2002
- Article first published online: 15 NOV 2002
- Manuscript Accepted: 19 JUN 2002
- Manuscript Revised: 29 MAY 2002
- Manuscript Received: 3 OCT 2001
- prostatic neoplasm;
Evidence suggests the type of treatment received for prostate carcinoma is associated with comorbidity, but little information is available on associations with specific comorbid disease or symptoms. The authors examined the relations between treatment and comorbidity, specific comorbid disease, and symptoms.
Medical records were abstracted for 1054 male members of the Kaiser Permanente medical care program diagnosed with prostate carcinoma from 1975 to 1987. Information was obtained on demographic characteristics, comorbid conditions, symptoms, tumor stage and grade, and treatment. Logistic regression was used to determine the significant predictors of treatment (radiation vs. nonaggressive treatment and surgery vs. nonaggressive treatment).
Compared to nonaggressive treatment, radiation treatment was less likely among men who had prior cancer (adjusted odds ratio [OR] 0.29, 95% confidence interval [CI] 0.09–0.90) or cerebrovascular disease (OR 0.33, 95% CI 0.13–0.83). There was a significant interaction between race and myocardial infarction (P = 0.02). Surgery, compared to nonaggressive treatment, was less common among men with a prior cancer (OR 0.21, 95% CI 0.07–0.63) or congestive heart failure (OR 0.29, 95% CI 0.09–0.90). Significant interactions were observed between race and myocardial infarction (P = 0.01), diabetes and dysuria or hematuria (P = 0.02), and para- or hemiplegia and urinary frequency or nocturia (P = 0.01).
Specific symptoms and comorbidity appear to influence treatment for prostate carcinoma. More research is needed on treatment differences by race. Cancer 2002;95:2308–15. Published 2002 by the American Cancer Society.